Loading
Cancer Research and Treatments · Journal article
Biomedical Materials Science · September 4, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review appraising emerging non-antibiotic antimicrobial strategies (nanoparticles, peptides, bacteriophages, probiotics, CRISPR, immune modulators, plant bioactives, biomaterials) as potential complements to antibiotics. Most candidates remain at preclinical or in vitro stage; only selected bacteriophage, peptide, silver-based, and host-directed therapies have entered clinical development, and the review concludes these are unlikely to replace conventional antibiotics but may diversify antimicrobial mechanisms if validated in rigorous clinical studies.
Narrative review. Global population at risk from antimicrobial resistance; no specific patient cohort studied in this review.. Intervention: Emerging non-antibiotic antimicrobial strategies: nanoparticles, antimicrobial peptides, bacteriophages, probiotics, postbiotics, CRISPR-Cas systems, immune modulators, plant-derived bioactives, biomaterial-based platforms, and nanomateria…. Compared with: Conventional antibiotics; some strategies evaluated against resistance determinants including impaired drug uptake, active efflux, enzymatic inactivation, target-site modification, biofilm tolerance, and horizontal gene transfer..
Antimicrobial resistance projected to contribute to up to 10 million deaths annually by 2050 with economic losses exceeding US$3.4 trillion in absence of intervention Emerging strategies include nanoparticles, antimicrobial peptides, bacteriophages, probiotics, postbiotics, CRISPR-Cas, immune modulators, plant bioactives, and biomaterial-based platforms Several bacteriophage, antimicrobial peptide, silver-based, and host-directed therapies have entered clinical development
Most emerging strategies remain at in vitro or preclinical stage and face substantial barriers: toxicity, pharmacokinetics, delivery, manufacturing scalability, reproducibility, regulatory complexity
Clinicians should recognize this as a synthesis of emerging research rather than evidence-based guidance for current practice. The review underscores that conventional antibiotics remain the standard of care and that non-antibiotic alternatives, though promising in concept, require substantial rigorous clinical validation before clinical adoption.
A narrative review synthesizing preclinical and early clinical evidence on emerging non-antibiotic antimicrobial strategies, most remaining at in vitro or preclinical stage, designed to frame research questions rather than answer them with rigorous comparative data.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize this as a synthesis of emerging research rather than evidence-based guidance for current practice. The review underscores that conventional antibiotics remain the standard of care and that non-antibiotic alternatives, though promising in concept, require substantial rigorous clinical validation before clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Antimicrobial resistance (AMR) constitutes one of the most pressing threats to global health security and is projected to contribute to up to 10 million deaths annually by 2050, with associated economic losses exceeding US$3.4 trillion in the absence of effective intervention. This critical narrative review synthesizes current evidence on emerging non-antibiotic strategies—including nanoparticles, antimicrobial peptides, bacteriophages, probiotics and postbiotics, CRISPR-Cas systems, immune modulators, plant-derived bioactives, and biomaterial-based platforms—as potential complements or alternatives to conventional antibiotics. Particular attention is given to the mechanisms through which these approaches may overcome or mitigate major resistance determinants, including impaired drug uptake, active efflux, enzymatic inactivation, target-site modification, biofilm-associated tolerance, and horizontal gene transfer. The review further examines the integration of nanomaterials into antimicrobial coatings, hydrogels, implant-associated infection management, tissue-engineering scaffolds, and advanced drug-delivery systems, with emphasis on localized antimicrobial activity, controlled therapeutic release, and the potential to integrate infection control with tissue regeneration. Translational maturity is critically appraised by distinguishing preclinical evidence from interventions that have progressed to human clinical evaluation. Although several bacteriophage, antimicrobial peptide, silver-based, and host-directed therapies have entered clinical development, most emerging strategies remain at the in vitro or preclinical stage and face substantial barriers related to toxicity, pharmacokinetics, delivery, manufacturing scalability, reproducibility, and regulatory complexity. Collectively, current evidence suggests that these approaches are unlikely to constitute universal replacements for conventional antibiotics; rather, their principal value lies in diversifying antimicrobial mechanisms, enabling targeted interventions, and reducing reliance on antibiotics. Realizing their clinical potential will require rigorous validation in well-designed clinical studies, scalable and reproducible manufacturing, and integration within antimicrobial stewardship and One Health frameworks.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.